TUCSON, Ariz.–HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today announced the appointment of Pete Clemens to Senior Vice President of Commercial Operations. Clemens’ primary responsibility will be leading global sales and commercialization efforts. Clemens joins HTG from Becton Dickinson & Company (BD), worldwide manufacturer of healthcare services and products, where he spent 10 years in positions of increasing responsibility. Most recently, he was Vice President, Distributor, OEM and Strategic Account Management and in this role he restructured agreements with BD’s top distributors and surpassed sales goals for three consecutive years. He also created and managed a customer-direct sales program. “Pete brings a wealth of experience and a proven track record in building teams and driving sales in a number of relevant industries including clinical diagnostics, biopharmaceuticals and medical-surgical product sales,” said TJ Johnson, President and CEO, HTG. “Pete complements our strong management team and will help accelerate our transition into a market-driven, customer-focused organization. “I am excited to join the HTG management team. HTG’s time and cost saving technology platform is versatile and valuable for both drug discovery and academia. There is enormous, untapped potential for this technology to assist in the advancement of research, drug discovery and the development of better therapies which ultimately improve patient care and quality of life,” said Pete Clemens. Prior to BD, Clemens was Vice President of Sales and Corporate Accounts at BIOGENEX where he helped reposition the company. He also held sales management positions at Dade Behring, Inc., Baxter Healthcare Corporation and American Hospital Supply Corporation. Clemens earned a BSB in Business Administration from the University of Minnesota. HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform allows scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification. The platform provides high-quality quantitative test results enabling clients to compress drug discovery and development program timelines, increase program success and reduce costs. About HTG Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.